Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Yorkers Get a Sneak Peek at alli®


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Adhesions
Amebiasis
More...

Related Healthscout Videos
 border=
Hungry Heart
Power Out Fat
Diabetes As a Risk Factor
Strategies in Treating Heart Disease
More...

Related Animations
 border=
Allergy
GERD
PPI Therapy
What is Cholesterol?
More...

Related Drug Information
 border=
Aciphex
Klor-Con
Klor-Con ER
Nexium
More...

Related News Articles
 border=
Low Vitamin D Tied to Depression in Older Adults
FDA Panel Considers Toll-Free Number for TV Drug Ads
Vitamin D Use Linked to Lower Mortality in Kidney Patients
Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

Marketed to overweight adults over age 18, alli is expected to cost between $1 and $2 a day. It works by blocking the body's absorption of fat.

It's designed not to have an adverse effect on the cardiovascular system as did other weight-loss products such as ephedra, Cadle said. The FDA banned ephedra after medical evidence indicated it increased heart attack risk.

Alli is not without its critics, however, chief among them Dr. Sidney M. Wolfe, director of Public Citizen's Health Research Group in Washington, D.C., who has spoken against orlistat's side effects before.

Text Continues Below



When another pharmaceutical company, Roche, marketed orlistat in prescription strength as Xenical, Wolfe spoke out. "Animal studies done by Roche show that rats developed aberrant crypti foci, ACF, precancerous lesions in the colon from Orlistat, which put them at higher risk of colon cancer," Wolfe said in a recent interview. "An independent study by researchers in 2006 found the same thing."

But another expert said Wolfe's concerns are unfounded.

"There are more than 100 clinical studies, including 30,000 clinical trial patients, and nine years of post-marketing surveillance with more than 29 million patient treatments, all showing no such risk with orlistat use," said Dr. Vidhu Bansal, director of medical affairs for GlaxoSmithKline Consumer Healthcare. "The FDA concluded the same in their recent review," she added.

Wolfe maintained that the FDA relied heavily on testimony by a panel comprised of pharmaceutical company representatives. But that is only part of the difficulty, he said. The side effects were embarrassing, dramatic and distasteful enough to cause orlistat to lose popularity.

"The RX (prescription) drug's popularity went down, because it caused all sorts of acute problems, mainly gastrointestinal," Wolfe said. "Twenty-five percent of people got oily spotting (from the rectum), because the fat is going in one end and coming out the other. You definitely wouldn't want to take it while on a first date."

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 5/22/2007

Related Links
 border=
From Healthscout's partner site on cholesterol, CholesterolNetwork.com
VIDEO: Open Arteries with a Cancer Drug
ONLINE TEST: Take our Home Body Fat Test!
QUIZ: Recommended Daily Calories and Fat





New Features

New ADHD Site!

SOURCES: Joe Cadle, marketing director, GlaxoSmithKline Consumer Healthcare, Pittsburgh, Pa.; Vidhu Bansal, Pharm D., director, medical affairs, GlaxoSmithKline Consumer Healthcare, Parsippany, N.J.; Sidney M. Wolfe, M.D., director, Public Citizens' Health Researtch Group, Washington, D.C.


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map